Request for Information/Rough Order of Magnitude for Manufacturing Process Development of 4-Hydroxybenzoic acid

Sources Sought
Person of Contact Maureen Wilson (maureen.wilson2@nih.gov)
Proposal Due Date Friday, June 5, 2026 (Closed 5 days 5 hours ago)
NAICS Codes 541714, 541715
  • Research Category Research & Development Services & Subcontracts
  • Solicitation Number S26-XX51
  • NCI OA Contract Number 75N91019D00024 – NCI-FFRDC

Description

The Frederick National Laboratory for Cancer Research (FNLCR), a Federally Funded Research and Development Center (FFRDC), currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute, is seeking information regarding Manufacturing Process Development of 4‑Hydroxybenzoic acid (4-HB). The project objectives include, but not limited to, assay validation and accelerated/short term stability; feasibility batch for accelerated stability study; manufacture clinical batch drug product; and stability studies of clinical supplies.

Proposal Instructions

Please contact Maureen Wilson at maureen.wilson2@nih.gov for a copy of S26-XX51- Request for Information/Rough Order of Magnitude.

Specific questions regarding this RFI may be directed to Maureen Wilson at maureen.wilson2@nih.gov no later than 4:00 p.m. (ET) Tuesday, May 26, 2026.

RFI responses to be emailed to Maureen Wilson and Jennifer Gnuschke at maureen.wilson2@nih.gov and gnuschkj@mail.nih.gov by 4:00 p.m. (ET) Friday, June 5, 2026.